CD16(+) fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. Liu X, Lu Y, Huang J, Xing Y, et al. Cancer Cell 2022;40:1341-1357.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu X, Lu Y, Huang J, Xing Y, et al. CD16(+) fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. Cancer Cell 2022;40:1341-1357.
PMID: 36379207